Aficamten vs Mavacamten: Which Is Better for Hypertrophic Cardiomyopathy?
Introduction The treatment landscape for hypertrophic cardiomyopathy (HCM) has dramatically evolved over the past few years. For decades, patients relied primarily on beta-blockers, calcium channel blockers, or invasive procedures like septal myectomy. However, the introduction of cardiac myosin inhibitors revolutionized care. Today, the debate of Aficamten vs Mavacamten is central to discussions among cardiologists, pharmacists, …
